摘要
目的评价抗菌新药利奈唑胺对肠球菌的体外抗菌作用。方法采用Microscan进行鉴定,药物敏感实验测定最小抑菌浓度(MIC)值,用WHONET5.3进行数据分析。结果肠球菌中屎肠球菌和粪肠球菌分离率为52.1%和45.8%;从泌尿系感染患者尿液中分离的肠球菌占第一位,占总分离率的54.1%,其次为脓液,分泌物,血液,痰,胆汁等。对庆大霉素高水平耐药的肠球菌(HLAR)的分离率为60.4%,未检出耐万古霉素的肠球菌(VRE),但检出万古霉素中介的肠球菌(VIE)为2.1%。结论利奈唑胺对肠球菌的控制有重要作用,故临床应慎用利奈唑胺,临床微生物学专家应密切关注利奈唑胺MIC值的变化,保护利奈唑胺的使用寿命。
Objective To evaluate linezolid sensitivity to enterococci. Methods Microscan was used to identify the minimal inhibitory concentration （MIC） of drug sensitivity, the data was analysed by WHONET 5.3. Results In 48 strains of enterococci, E.faeium and E.faecalis of enterococci separated rates were 52.1% and 45.8%. Enterococci separated rates from urine samples got ahead with 54.1%, then pus, secretion, blood, sputum and bile etc. High level gentamicin resistant enterococci （HLAR） separated rate was 60.4%. The detectable rate of vancomycin-intermediate enterococci （VIE） was 2.1%, concurrently without vancomycin-resistant ones. Conclusions Linezolid play an important role in controlling enterococci infection.
出处
《实验与检验医学》
CAS
2009年第5期451-452,460,共3页
Experimental and Laboratory Medicine
